Last updated: April 23, 2026
What companies supply lamivudine and zidovudine API and key intermediates?
Lamivudine and zidovudine are mature nucleoside reverse transcriptase inhibitor (NRTI) products with broad, long-running generic supply chains. Below is a supplier set you can use for sourcing strategy across API and intermediate manufacturing, focused on businesses that publicly disclose API manufacture or are established API suppliers to global markets.
Who supplies lamivudine API?
Common API suppliers and manufacturers (global, including China and India ecosystems):
- Hetero Drugs (India)
- Cipla (India)
- Mylan / Viatris (global; API and finished dosage presence)
- Natco Pharma (India; broader antiretroviral footprint)
- Hubei Biocause Pharmaceutical (China; API/intermediates model in the NRTI space)
- Zhejiang Jinhua Pharmaceutical / Zhejiang Jinhua (China; legacy API supplier footprint)
- Aurobindo Pharma (India; API manufacturing platform)
- Sun Pharma (India; API and finished products platform)
Lamivudine API sourcing is also frequently routed through contract API/intermediate manufacturers specializing in nucleosides and antiviral intermediates in China and India, often under ODM-type arrangements for generic manufacturers.
Who supplies zidovudine API?
Zidovudine API is similarly widely sourced from established API manufacturers:
- Hetero Drugs (India)
- Cipla (India)
- Aurobindo Pharma (India)
- Sun Pharma (India)
- Mylan / Viatris (global; API and finished dosage presence)
- Natco Pharma (India)
- Hubei Biocause Pharmaceutical (China; nucleoside API/intermediate capability)
- Zhejiang Jinhua Pharmaceutical / Zhejiang Jinhua (China; legacy API supplier footprint)
Zidovudine supply often depends on access to key nucleoside building blocks (sugar moiety intermediates and nucleobase coupling steps) and solvent reagents that drive impurity profiles and regulatory acceptance.
Which companies supply both lamivudine and zidovudine (shared vendor strategy)?
Using a shared-vendor approach reduces qualification variance across analytical methods, impurity trends, and change-control governance.
- Hetero Drugs (India)
- Cipla (India)
- Aurobindo Pharma (India)
- Sun Pharma (India)
- Natco Pharma (India)
- Mylan / Viatris (global)
For China-based sourcing, companies that sit in the nucleoside API and intermediate manufacturing cluster (such as Hubei Biocause) are often active across multiple NRTIs, including lamivudine and zidovudine. Final confirmation should be driven by CoA coverage and batch record review at onboarding.
What intermediate suppliers matter for these APIs?
For nucleoside APIs like lamivudine and zidovudine, procurement is typically organized around:
- Sugar moiety intermediates (phosphorylated and protected forms, depending on synthetic route)
- Nucleobase coupling intermediates (cyclization and amination chemistry upstream)
- Protection/deprotection reagents and catalysts (impact impurity and residuals)
- Solvents and dehydrating agents (residual solvent specifications drive GMP controls)
In practice, large API suppliers either:
- manufacture these intermediates in-house, or
- source them from specialist intermediate plants, then control through supplier qualification and incoming impurity testing.
Because many intermediate suppliers do not list specific customer APIs publicly, intermediate procurement is more reliably structured through supplier qualification rather than name-based targeting.
How to screen suppliers for lamivudine and zidovudine quickly (qualification checklist)
Use a qualification gate that ties directly to regulatory and manufacturing risk:
Documentation and quality system
- GMP status for API manufacture (inspection history and scope coverage)
- Batch release documentation standard (CoA content, impurity specification coverage)
- Change-control discipline (process, site, raw material, and analytical method changes)
Analytical and impurity control
- Impurity profile fit to pharmacopeia and finished dosage specifications
- Residual solvent compliance
- Stability data availability for API storage conditions
Supply assurance
- Minimum order quantities and lead times
- Multi-source availability strategy (duplicate suppliers)
- Capacity disclosure for planned ramps
What supply-chain pattern dominates for these mature APIs?
Lamivudine and zidovudine are mature, off-patent products. Supply typically follows two parallel paths:
- Large integrated generics with API manufacturing (India-based leaders) that supply both API and finished formulations.
- API-only and intermediate-heavy manufacturers (common in China) supplying multiple NRTIs into global generics.
That creates a supplier set where qualification outcomes often hinge on impurity controls and residuals rather than the ability to make the molecules.
Key Takeaways
- Lamivudine and zidovudine API supply is broad with established manufacturers across India and China.
- Short-list overlap is strong for India-based integrated players: Hetero, Cipla, Aurobindo, Sun Pharma, Natco and Mylan/Viatris.
- Intermediate-driven quality risk is the main differentiator; supplier onboarding should prioritize impurity and residual solvent controls tied to your target specification.
- Use a two-tier sourcing strategy: one primary qualified API supplier plus one qualified secondary supplier, both supported by audit-ready documentation and consistent impurity control.
FAQs
1) Can one supplier cover both lamivudine and zidovudine reliably?
Yes. Several established generic API manufacturers have antiretroviral production footprints that cover both molecules, enabling shared qualification practices and more consistent change-control management.
2) What is the most common reason zidovudine or lamivudine API batches fail acceptance?
Impurity profile drift and residuals (including residual solvents) are the primary failure modes, not endpoint yield.
3) Are China-based API manufacturers suitable for these APIs?
They often are, since the molecules are mature and widely produced. Supplier suitability is determined by GMP inspection scope, impurity consistency, and audit outcomes, not by geography.
4) Is intermediate sourcing a key constraint?
It is a key constraint because nucleoside intermediates and reagents drive impurity generation. Even when intermediates are sourced externally, the API supplier’s incoming controls and final impurity controls determine regulatory fit.
5) Should finished dosage manufacturers be treated as API suppliers?
Some do supply APIs as part of broader operations, but sourcing from finished dosage manufacturers should be handled with the same API GMP, CoA completeness, and batch traceability requirements.
References (APA)
[1] European Medicines Agency. (n.d.). Human medicines: Public assessments and European Public Assessment Reports (EPARs). https://www.ema.europa.eu/
[2] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] World Health Organization. (n.d.). WHO Model List of Essential Medicines. https://www.who.int/
[4] Pharmaceutical Inspection Co-operation Scheme (PIC/S). (n.d.). Public information and members. https://picscheme.org/
